The study objective is to evaluate the efficacy and safety of oral YM150 for 52 weeks in patients with a history of venous thromboembolism.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
87
oral
Unnamed facility
Chugoku, Japan
Unnamed facility
Chūbu, Japan
Unnamed facility
Kansai, Japan
Unnamed facility
Kantou, Japan
Unnamed facility
Tōhoku, Japan
Joint incidence of deep vein thromboembolism or pulmonary thromboembolism
Time frame: 52 weeks
Incidence of each thromboembolism
Time frame: 52 weeks
All cause mortality
Time frame: 52 weeks
Incidence of bleeding event
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.